Oral Oncology Reports最新文献

筛选
英文 中文
Comment on “Hypofractionated adjuvant radiotherapy in cutaneous squamous cell and basal cell carcinoma of the head and neck: 50 (Gy) in 20 study” “低分割辅助放疗治疗头颈部皮肤鳞状细胞癌和基底细胞癌:50 (Gy)在20项研究中的评论”
Oral Oncology Reports Pub Date : 2025-04-11 DOI: 10.1016/j.oor.2025.100739
Efsun Somay , Erkan Topkan , Ugur Selek
{"title":"Comment on “Hypofractionated adjuvant radiotherapy in cutaneous squamous cell and basal cell carcinoma of the head and neck: 50 (Gy) in 20 study”","authors":"Efsun Somay , Erkan Topkan , Ugur Selek","doi":"10.1016/j.oor.2025.100739","DOIUrl":"10.1016/j.oor.2025.100739","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100739"},"PeriodicalIF":0.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing efficacy and safety of weekly vs. triweekly cisplatin concurrently with radiotherapy for locally advanced head and neck cancer: Systematic review and meta-analysis 比较每周顺铂与三周顺铂联合放疗治疗局部晚期头颈癌的疗效和安全性:系统评价和荟萃分析
Oral Oncology Reports Pub Date : 2025-04-08 DOI: 10.1016/j.oor.2025.100738
Mohammed Amine Saâd , Imad Taleb , Sofia El Omri , Hamadoun Traoré , Imane Chahbounia , Choukri Elm'hadi , Saïda Lamine , Mohammed Anouar Mokhlis , Lamia Aalaoui , Mohamed Reda Khmamouche , Khaoula Alaoui Slimani , Yassir Sbitti , Tarik Mahfoud , Hassan Errihani , Mohamed Ichou , Rachid Tanz
{"title":"Comparing efficacy and safety of weekly vs. triweekly cisplatin concurrently with radiotherapy for locally advanced head and neck cancer: Systematic review and meta-analysis","authors":"Mohammed Amine Saâd ,&nbsp;Imad Taleb ,&nbsp;Sofia El Omri ,&nbsp;Hamadoun Traoré ,&nbsp;Imane Chahbounia ,&nbsp;Choukri Elm'hadi ,&nbsp;Saïda Lamine ,&nbsp;Mohammed Anouar Mokhlis ,&nbsp;Lamia Aalaoui ,&nbsp;Mohamed Reda Khmamouche ,&nbsp;Khaoula Alaoui Slimani ,&nbsp;Yassir Sbitti ,&nbsp;Tarik Mahfoud ,&nbsp;Hassan Errihani ,&nbsp;Mohamed Ichou ,&nbsp;Rachid Tanz","doi":"10.1016/j.oor.2025.100738","DOIUrl":"10.1016/j.oor.2025.100738","url":null,"abstract":"<div><h3>Background</h3><div>Cisplatin-based chemotherapy is widely used in the treatment of locally advanced head and neck cancer (HNC). The optimal dosing schedule, whether weekly or triweekly, has been a subject of debate. This study aims to evaluate the efficacy and safety of weekly versus triweekly cisplatin regimens in this patient population.</div></div><div><h3>Material and methods</h3><div>In accordance with the PRISMA guidelines, we conducted this meta-analysis to compare outcomes associated with weekly and triweekly cisplatin regimens. The endpoints examined were overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), locoregional recurrence-free survival (LRRFS) and safety. This meta-analysis protocol was registered in PROSPERO (CRD42023461292).</div></div><div><h3>Results</h3><div>The analysis of survival outcomes demonstrated no difference between the two schedules in terms of OS, PFS, LRRFS and DMFS at 2 and 3 years and 5 years (except for 2 years LRRFS). The odds ratio of OS at 2 years was 1.02 (p = 0.87) at 3 years 0.90 (p = 0.46) and at 5 years 1.13 (p = 0.59), and for PFS at the OR 2 years was 0.97 (p = 0.85) at 3 years 0.87 (p = 0.30) and at 5 years 0.86 (p = 0.55). Triweekly was superior to weekly cisplatin in terms of short-term LRRFS (at 2 years), with an OR of 1.57 (p = 0.02). Both protocols were similar in terms of adverse events.</div></div><div><h3>Conclusion</h3><div>Both weekly and triweekly cisplatin regimens show comparable survival outcomes and safety profiles in patients with head and neck cancers, except for short term LRRFS (at 2 years). These findings suggest that treatment decisions should be tailored to the patient's individual profile, including comorbidities and tolerability. Future studies should explore cumulative dosing and biomarkers to refine treatment strategies further.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100738"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Change of skeletal muscle mass and associated factors during radiotherapy and chemoradiotherapy in patients with head and neck squamous cell carcinoma 头颈部鳞状细胞癌患者放疗和化疗期间骨骼肌质量的变化及相关因素
Oral Oncology Reports Pub Date : 2025-03-28 DOI: 10.1016/j.oor.2025.100737
Anouk W.M.A. Schaeffers , Hannah A. Scholten , Annemieke Kok , Floris C.J. Reinders , Rebecca K. Stellato , Ernst J. Smid , Maartje A. van Beers , Carla H. van Gils , Caroline M. Speksnijder , Marielle P. Philippens , Lot A. Devriese , Remco de Bree
{"title":"Change of skeletal muscle mass and associated factors during radiotherapy and chemoradiotherapy in patients with head and neck squamous cell carcinoma","authors":"Anouk W.M.A. Schaeffers ,&nbsp;Hannah A. Scholten ,&nbsp;Annemieke Kok ,&nbsp;Floris C.J. Reinders ,&nbsp;Rebecca K. Stellato ,&nbsp;Ernst J. Smid ,&nbsp;Maartje A. van Beers ,&nbsp;Carla H. van Gils ,&nbsp;Caroline M. Speksnijder ,&nbsp;Marielle P. Philippens ,&nbsp;Lot A. Devriese ,&nbsp;Remco de Bree","doi":"10.1016/j.oor.2025.100737","DOIUrl":"10.1016/j.oor.2025.100737","url":null,"abstract":"<div><h3>Background and purpose</h3><div>The aim is to investigate whether lumbar skeletal muscle index (LSMI) decreases during treatment of head and neck squamous cell carcinoma (HNSCC) patients, and which pre-treatment variables are associated with change.</div></div><div><h3>Materials and methods</h3><div>The LSMI before and during treatment was assessed using MRI scans of HNSCC patients treated with radiotherapy (RT) or chemoradiotherapy (CRT). Mixed models assessed LSMI change and pre-treatment covariates (i.e. age, BMI, tumor characteristics and treatment type).</div></div><div><h3>Results</h3><div>In 63 patients the LSMI decreased from 40.56 cm<sup>2</sup>/m<sup>2</sup> to 39.96 cm<sup>2</sup>/m<sup>2</sup> (<em>p</em> trend = 0.008) on average. The LSMI of CRT patients decreased more than the LSMI of RT patients, but this was not significant (40.85–39.63 cm<sup>2</sup>/m<sup>2</sup> vs. 40.37 to 40.19 cm<sup>2</sup>/m<sup>2</sup>; p-interaction = 0.052). No effects of pre-treatment covariates on the LSMI trend over time were observed.</div></div><div><h3>Conclusion</h3><div>LSMI decreased during treatment in HNSCC patients, which was not related to pre-treatment variables, but seemed slightly larger for CRT patients than RT patients.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100737"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sinonasal primary squamous cell carcinoma: A case report to illustrate key diagnostic and therapeutic considerations in managing sinonasal squamous cell carcinoma 鼻窦炎原发鳞状细胞癌:一个病例报告说明鼻窦炎鳞状细胞癌的诊断和治疗要点
Oral Oncology Reports Pub Date : 2025-03-26 DOI: 10.1016/j.oor.2025.100736
A.C. Drossaert , G.K.P. Bittermann , P.A.W.H. Kessler
{"title":"Sinonasal primary squamous cell carcinoma: A case report to illustrate key diagnostic and therapeutic considerations in managing sinonasal squamous cell carcinoma","authors":"A.C. Drossaert ,&nbsp;G.K.P. Bittermann ,&nbsp;P.A.W.H. Kessler","doi":"10.1016/j.oor.2025.100736","DOIUrl":"10.1016/j.oor.2025.100736","url":null,"abstract":"<div><div>Sinonasal squamous cell carcinoma (SNSCC) is a rare malignancy that affects the nasal cavity and paranasal sinuses, representing only 3 % of nasopharyngeal malignancies. It predominantly affects the maxillary sinus, with less frequent involvement of the ethmoid and sphenoid sinuses. SNSCC typically presents with nonspecific symptoms such as epistaxis, pain, and signs of ulceration, often leading to a delayed diagnosis. Due to its late presentation, aggressive nature, and potential for recurrence, SNSCC presents significant challenges in diagnosis and management. A representative clinical case is described to emphasize the importance of a multidisciplinary approach regarding the diagnosis and treatment in managing SNSCC.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100736"},"PeriodicalIF":0.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deciphering oral cancer subtypes: Integrating differential gene expression and pathway analysis followed by non-negative matrix factorization transcription analysis 解密口腔癌亚型:整合差异基因表达和通路分析,然后进行非负性基质因子化转录分析
Oral Oncology Reports Pub Date : 2025-03-24 DOI: 10.1016/j.oor.2025.100735
Anoop Kumar Tiwari , Devansh Jain , Jayesh Kumar Tiwari , Shyam Kishore , Akhilesh Kumar Singh , Sushant Kumar Shrivastava , Arun Khattri
{"title":"Deciphering oral cancer subtypes: Integrating differential gene expression and pathway analysis followed by non-negative matrix factorization transcription analysis","authors":"Anoop Kumar Tiwari ,&nbsp;Devansh Jain ,&nbsp;Jayesh Kumar Tiwari ,&nbsp;Shyam Kishore ,&nbsp;Akhilesh Kumar Singh ,&nbsp;Sushant Kumar Shrivastava ,&nbsp;Arun Khattri","doi":"10.1016/j.oor.2025.100735","DOIUrl":"10.1016/j.oor.2025.100735","url":null,"abstract":"<div><div>Oral cancer is a major public health concern around the globe, and its classification relies on factors such as habitual status and tumor stages. However, a significant gap exists in understanding oral cancer patients' molecular and genomic characteristics. This study aims to bridge this gap by analyzing International Cancer Genome Consortium (ICGC's) oral cancer data, which identified 2270 differentially expressed genes related to oral cancer. We employed pathway enrichment analysis, highlighting key pathways including hypoxia, VEGF, PI3K, and TGF-β, and STAT2, E2F4, and SP1 transcription factors enriched in tumor samples compared to normal samples. Moreover, we utilized a non-negative matrix factorization (NMF) technique for unsupervised subtype discovery and identified three distinct tumor subgroups. Each subgroup exhibited unique molecular profiles, with pathways related to TNF-α, NF-κB, and hypoxia enriched across all groups. Notably, transcription factor analysis revealed crucial differences: subgroup A was enriched in EGR1, TP53, and HIF1A; subgroup B showed high levels of CDX2 and HNF4A; while subgroup C was characterized by enrichment in ATF4 and E2F4. These findings suggest the feasibility of classifying oral squamous cell carcinoma (OSCC) patients based on gene expression profiles, laying a foundational framework for future research aimed at personalized treatment strategies.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100735"},"PeriodicalIF":0.0,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Swallowing function, body image and uncertainty in illness after reconstruction in oral cancer survivors 口腔癌幸存者重建后的吞咽功能、身体形象和疾病的不确定性
Oral Oncology Reports Pub Date : 2025-03-17 DOI: 10.1016/j.oor.2025.100734
Chen-Chan Kuo , Shiu-Yu C. Katie Lee , Chun-Ta Liao
{"title":"Swallowing function, body image and uncertainty in illness after reconstruction in oral cancer survivors","authors":"Chen-Chan Kuo ,&nbsp;Shiu-Yu C. Katie Lee ,&nbsp;Chun-Ta Liao","doi":"10.1016/j.oor.2025.100734","DOIUrl":"10.1016/j.oor.2025.100734","url":null,"abstract":"<div><h3>Background</h3><div>Swallowing and body image are the main concerns after reconstruction for oral cancer. Perceiving uncertainty or an unpredictable future is a significant psychosocial stressor in cancer survivors. This study aimed to explore swallowing function, body image, and uncertainty after the reconstruction for oral cancer, and to examine their associations.</div></div><div><h3>Methods</h3><div>A consecutive sample of 155 oral cancer adults (147 males and 8 females), with or without adjuvants, and surviving 3–30 months after primary microvascular free flaps, were included. The main outcomes were assessed by the Body Image Scale, EORTC QLQ-HN 35, and Mishel's Uncertainty in Illness Scale.</div></div><div><h3>Results</h3><div>Participants reported moderate disturbance in appearance, body as a whole, and sexual attraction, and a moderate-to-low level of EORTC swallowing, speech, and social problems. Less than 20 % have pursued cosmetic surgeries after reconstruction. After adjusting for demographic and clinical factors, poor body image (<em>β</em> = .318), poor speech (<em>β</em> = .198), lower household incomes (<em>β</em> = -.153), and farmers v.s. counterparts were more likely to have higher uncertainty in illness (Adj.R<sup>2</sup> = .347).</div></div><div><h3>Conclusions</h3><div>Along with body image disturbance and swallowing problems, financial burden or work-related stress are significant risk factors for higher uncertainty in illness. Providing supportive care to cope with body image disturbances, swallowing and speech problems, and to improve work or financial status are warranted to help oral cancer survivors to cope with uncertainty in illness after free flaps.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100734"},"PeriodicalIF":0.0,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143851608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on “Resection of a left carotid body tumor in a young female patient” “1例年轻女性患者左侧颈动脉体肿瘤切除术”评论
Oral Oncology Reports Pub Date : 2025-03-13 DOI: 10.1016/j.oor.2025.100733
Lucas Alves da Mota Santana , Lara Góis Floresta , Rajiv Gandhi Gopalsamy , Bernardo Ferreira Brasileiro , Cleverson Luciano Trento , Lysandro Pinto Borges
{"title":"Comment on “Resection of a left carotid body tumor in a young female patient”","authors":"Lucas Alves da Mota Santana ,&nbsp;Lara Góis Floresta ,&nbsp;Rajiv Gandhi Gopalsamy ,&nbsp;Bernardo Ferreira Brasileiro ,&nbsp;Cleverson Luciano Trento ,&nbsp;Lysandro Pinto Borges","doi":"10.1016/j.oor.2025.100733","DOIUrl":"10.1016/j.oor.2025.100733","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100733"},"PeriodicalIF":0.0,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypofractionated adjuvant radiotherapy in cutaneous squamous cell and basal cell carcinoma of the head and neck: 50(Gy) in 20 study 低分割辅助放疗治疗头颈部皮肤鳞状细胞癌和基底细胞癌:20项研究中50 Gy
Oral Oncology Reports Pub Date : 2025-03-01 DOI: 10.1016/j.oor.2025.100732
Marcus Hu , Howard Liu , Anne Bernard , Michael Efendy , Sandro V. Porceddu
{"title":"Hypofractionated adjuvant radiotherapy in cutaneous squamous cell and basal cell carcinoma of the head and neck: 50(Gy) in 20 study","authors":"Marcus Hu ,&nbsp;Howard Liu ,&nbsp;Anne Bernard ,&nbsp;Michael Efendy ,&nbsp;Sandro V. Porceddu","doi":"10.1016/j.oor.2025.100732","DOIUrl":"10.1016/j.oor.2025.100732","url":null,"abstract":"<div><h3>Purpose</h3><div>To assess clinical outcomes and tolerability of patients with cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) of the head and neck region, treated with adjuvant radiotherapy prescribed to a moderately hypofractionated regimen of 50Gy in 20 fractions.</div></div><div><h3>Methods and materials</h3><div>Eligibility for this retrospective study included patients with cutaneous SCC and BCC of the head and neck who received adjuvant radiotherapy to a dose of 50Gy in 20 fractions (2.5Gy per fraction) between 1/1/2007 and 31/12/2019 at a tertiary Queensland hospital. Primary endpoint was freedom from local failure (FFLF). Secondary outcomes were loco-regional recurrence-free survival (LRRFS), overall survival (OS) and toxicity rates. Acute toxicities were retrospectively collected and reported according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.</div></div><div><h3>Results</h3><div>A total of 126 patients were evaluated in this study with a median follow up period of 19.7 months (interquartile range 1.63–121.03). The median age was 68.3 years old. Twenty-six patients were immunosuppressed. Predominant histopathology was SCC (63.5 %). The majority were staged pT1-2 (74.6 %), and clinically or pathologically N0 (96.8 %). 122 patients received adjuvant radiotherapy to the primary tumour bed, and four patients received treatment both the primary and nodal region. FFLF was 95.8 % and 92.2 % at 2 and 5 years, respectively. No statistically significant clinico-pathological factors were prognostic of FFLF. LRRFS was 90.5 % at 2 years and 83.1 % at 5 years. OS was 88.7 % at 2 years and 69.9 % at 5 years. Five of the 21 deaths were related to the index cutaneous carcinoma. Grade 3 radiation dermatitis and mucositis occurred in 13.5 % and 4.0 % of patients, respectively. There were no grade 4/5 toxicities. Four patients required treatment breaks, of which two were planned breaks. No patient required enteral feeding during their RT course.</div></div><div><h3>Conclusion</h3><div>This is the largest series to date evaluating a single moderately hypofractionated adjuvant radiotherapy regimen for cutaneous SCC and BCC of the head and neck. This regimen was associated with high locoregional control and was well tolerated. A moderately hypofractionated course of adjuvant radiotherapy in cutaneous SCC and BCC can be a suitable option to reduce treatment duration.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100732"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143576889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral potentially malignant disorders: Challenges for patient participation due to opacity 口腔潜在恶性疾病:由于不透明,患者参与的挑战
Oral Oncology Reports Pub Date : 2025-03-01 DOI: 10.1016/j.oor.2025.100731
Brenda Bogaert
{"title":"Oral potentially malignant disorders: Challenges for patient participation due to opacity","authors":"Brenda Bogaert","doi":"10.1016/j.oor.2025.100731","DOIUrl":"10.1016/j.oor.2025.100731","url":null,"abstract":"<div><div>Opacity – or the lack of transparency - impacts patients' ability to participate in and contribute to decision-making. This contribution examines how opacity affects patient engagement in the context of oral potentially malignant disorders. The discussion focuses on three key areas: the effects of unclear disease classifications on patient perceptions of their health; the ways in which ambiguous healthcare pathways create barriers for both patients and providers; and the broader impact of opacity on patient autonomy. The conclusion explores strategies to reduce or mitigate these challenges, including fostering epistemic networks for patients and healthcare providers and embracing the value of humility in care work.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100731"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143592377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dysregulation of glucose-6-phosphate dehydrogenase in head and neck squamous cell carcinoma: Pathways, mutations, and therapeutic opportunities 头颈部鳞状细胞癌中葡萄糖-6-磷酸脱氢酶的失调:途径、突变和治疗机会
Oral Oncology Reports Pub Date : 2025-02-20 DOI: 10.1016/j.oor.2025.100726
Santhakumar Egambaram , Mohamed Rizwan Ghouse , Anishkiran Balasundar, Rajesh Parsanathan
{"title":"Dysregulation of glucose-6-phosphate dehydrogenase in head and neck squamous cell carcinoma: Pathways, mutations, and therapeutic opportunities","authors":"Santhakumar Egambaram ,&nbsp;Mohamed Rizwan Ghouse ,&nbsp;Anishkiran Balasundar,&nbsp;Rajesh Parsanathan","doi":"10.1016/j.oor.2025.100726","DOIUrl":"10.1016/j.oor.2025.100726","url":null,"abstract":"<div><h3>Objective</h3><div>Glucose-6-phosphate dehydrogenase <strong>(</strong>G6PD) deficiency, the most common human enzyme defect, confers malaria resistance and is linked to reduced cancer risk. Its upregulation in malignancies suggests a critical role in tumour progression. This study examines G6PD in head and neck squamous cell carcinoma (HNSCC), focusing on its expression, genetic alterations, interactions, and therapeutic potential.</div></div><div><h3>Materials and methods</h3><div>Bioinformatics tools, including UALCAN, Human Protein Atlas, GEPIA2, cBioPortal, muTarget, GeneMANIA, Cancer Hallmarks, and GSCA, were used to analyse expression, survival, genomic alterations, protein interactions, pathway enrichment, and drug sensitivity.</div></div><div><h3>Results</h3><div>G6PD is significantly upregulated in HNSCC, correlating with poor overall and disease-free survival. Genomic alterations predominantly involve amplification, while regulatory mutations in NFE2L2 and KEAP1 increase expression, and mutations in HRAS and TACC2 reduce it. Protein interaction analysis links G6PD to oxidative stress, tumour metabolism, and cell migration, with key interactions involving NFE2L2 and HRAS. Enrichment analysis associates G6PD with metastasis, immune evasion, and metabolic reprogramming. Drug sensitivity analysis reveals a complex relationship between G6PD expression and therapeutic response.</div></div><div><h3>Conclusion</h3><div>G6PD is critical in HNSCC progression and may serve as a prognostic biomarker and therapeutic target. Further experimental validation is required to explore G6PD inhibition as a treatment strategy, highlighting the importance of metabolic reprogramming in cancer therapy.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100726"},"PeriodicalIF":0.0,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143474822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信